Last reviewed · How we verify
HL237 tablet
At a glance
| Generic name | HL237 tablet |
|---|---|
| Sponsor | Hanlim Pharm. Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis (PHASE2)
- The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus (PHASE1)
- A Multiple Dose of HL237 in Healthy Male Subject (PHASE1)
- A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |